Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818147 | 0.94 | TDP1 (0.33) | TDP1 | |
| SCHEMBL6676603 | 0.92 | TDP1 (0.36) | TDP1 | |
| SCHEMBL29000774 | 0.92 | TDP1 (0.36) | TDP1 | |
| SCHEMBL5156789 | 0.88 | — | — | |
| SCHEMBL6209232 | 0.82 | ADH1C (0.36) | — | |
| SCHEMBL9217881 | 0.80 | — | — | |
| SCHEMBL4045334 | 0.80 | — | — | |
| SCHEMBL3982585 | 0.80 | — | — | |
| SCHEMBL6640905 | 0.80 | HIF1A (0.35) | — | |
| SCHEMBL4522063 | 0.79 | SLC22A6 (0.39) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059138-A1 | CHEMICAL LINKERS | SIGMA-ALDRICH CHEMICALS PRIVATE LIMITED (IN) | 2025-02-20 | — | — | US | disclosed |
| EP-4452945-A2 | CHEMICAL LINKERS | Sigma-Aldrich Co. LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023122481-A2 | CHEMICAL LINKERS | SIGMA-ALDRICH CO. LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-2894149-B1 | Cyanoguanidine prodrugs | LEO PHARMA AS (DK) | 2017-08-02 | — | — | EP | disclosed |
| EP-1339686-B1 | CYANOGUANIDINE PRODRUGS | LEO PHARMA AS (DK) | 2015-09-16 | — | — | EP | disclosed |
| EP-2894149-A1 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2015-07-15 | — | — | EP | disclosed |
| US-RE42353-E1 | Quinazoline derivatives and pharmaceutical compositions containing them | ASTRAZENECA UK LIMITED (GB) | 2011-05-10 | — | — | US | disclosed |
| US-20110071144-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 2011-03-24 | — | — | US | disclosed |
| US-7456202-B2 | Marked maleimide compounds, method for preparing same and use thereof for marking macromolecules | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-11-25 | — | — | US | disclosed |
| US-7365174-B2 | Azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-29 | — | — | US | disclosed |
| EP-0929530-B1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2002-11-20 | — | — | EP | disclosed |
| US-20020165201-A1 | Cyanoguanidine prodrugs | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-11-07 | — | — | US | disclosed |
| US-6414148-B1 | PRODUCE ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT IN WARM-BLOODED ANIMALS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
| WO-2002042265-A2 | CYANOGUANIDINE PRODRUGS | LEO PHARMA A/S (DK) | 2002-05-30 | — | — | WO | disclosed |
| EP-1209147-A1 | CARBOXYLIC ACID DERIVATIVES AND ADHESION MOLECULE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2002-05-29 | — | — | EP | disclosed |
| US-6096771-A | ISOXAZOLE DERIVATIVES EXHIBITING EXCELLENT TYPE B AND TYPE A MONOAMINE OXIDASE INHIBITORY ACTIVITIES, THEREFORE USEFUL FOR PREVENTING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| US-5965591-A | MONOAMINE OXIDASE INHIBITOR; FOR PROPHYLAXIS AND TREATING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 1999-10-12 | — | — | US | disclosed |
| EP-0929530-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013354-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
| EP-0779281-A1 | ISOXAZOLES | SANKYO COMPANY LIMITED (JP) | 1997-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165201-A1 | Cyanoguanidine prodrugs | CBR1, SIGMAR1, ROR1 | TDP1 2624/4885 |
| US-20250059138-A1 | CHEMICAL LINKERS | MDM2, ADRM1, USP36 | TDP1 3050/4885 |
| US-20110071144-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NR5A1, NR5A2, CNKSR1 | TDP1 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.